Tuesday - August 5, 2025
International Myeloma Foundation Brings Patient Voice, Science to FDA-ODAC Meeting - Advocates for BLENREP in Triplet Drug Combinations for Treatment of Relapsed/Refractory Myeloma
July 22, 2025
NORTH HOLLYWOOD, California, July 22 -- The International Myeloma Foundation issued the following news:

* * *

The International Myeloma Foundation Brings the Patient Voice and Science to FDA-ODAC Meeting; Advocates for BLENREP(R) (belantamab mafodotin) in Triplet Drug Combinations for the Treatment of Relapsed/Refractory Myeloma

ODAC votes against belantamab mafodotin in combination with bortezomib and dexamethasone (3-5), and in combination with pomalidomi . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products